Similar articles for PMID: 17607037

Year	Number of Results
1992	1
1994	1
1995	2
1997	1
1999	1
2000	2
2001	3
2002	1
2003	6
2004	2
2005	3
2006	4
2007	10
2008	3
2009	3
2010	1
2011	2
2012	4
2013	2
2014	3
2015	1
2019	1
2024	0

1

Carbon nanotubes: potential benefits and risks of nanotechnology in nuclear medicine.

Reilly RM. Reilly RM. J Nucl Med. 2007 Jul;48(7):1039-42. doi: 10.2967/jnumed.107.041723. J Nucl Med. 2007. PMID: 17607037 Free article. No abstract available.

2

Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes.

McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, Brentjens R, Scheinberg DA. McDevitt MR, et al. J Nucl Med. 2007 Jul;48(7):1180-9. doi: 10.2967/jnumed.106.039131. J Nucl Med. 2007. PMID: 17607040 Free article.

3

Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.

Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK, Press OW. Pagel JM, et al. Cancer Res. 2007 Jun 15;67(12):5921-8. doi: 10.1158/0008-5472.CAN-07-0080. Cancer Res. 2007. PMID: 17575162

4

H4octapa: an acyclic chelator for 111In radiopharmaceuticals.

Price EW, Cawthray JF, Bailey GA, Ferreira CL, Boros E, Adam MJ, Orvig C. Price EW, et al. J Am Chem Soc. 2012 May 23;134(20):8670-83. doi: 10.1021/ja3024725. Epub 2012 May 11. J Am Chem Soc. 2012. PMID: 22540281

5

Regressive DOTA labelling performance with indium-111 and yttrium-90 over a week of use.

Hainsworth JE, Mather SJ. Hainsworth JE, et al. Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1348. doi: 10.1007/s00259-005-1923-8. Eur J Nucl Med Mol Imaging. 2005. PMID: 16142470 No abstract available.

6

Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.

Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares CF, Epenetos AA. Kosmas C, et al. Cancer Res. 1992 Feb 15;52(4):904-11. Cancer Res. 1992. PMID: 1737353 Clinical Trial.

7

Oxygen adsorption by carbon nanotubes and its application in radiotherapy.

Yang J, Li W, Li Q, Wu S, Yu B, Jing X, Li W. Yang J, et al. IET Nanobiotechnol. 2007 Feb;1(1):10-4. doi: 10.1049/iet-nbt:20060017. IET Nanobiotechnol. 2007. PMID: 17500583 Review.

8

High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.

Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, DeNardo GL. Richman CM, et al. Clin Cancer Res. 2005 Aug 15;11(16):5920-7. doi: 10.1158/1078-0432.CCR-05-0211. Clin Cancer Res. 2005. PMID: 16115934 Clinical Trial.

9

Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents.

Harris TD, Cheesman E, Harris AR, Sachleben R, Edwards DS, Liu S, Bartis J, Ellars C, Onthank D, Yalamanchili P, Heminway S, Silva P, Robinson S, Lazewatsky J, Rajopadhye M, Barrett J. Harris TD, et al. Bioconjug Chem. 2007 Jul-Aug;18(4):1266-79. doi: 10.1021/bc070002+. Epub 2007 Jun 19. Bioconjug Chem. 2007. PMID: 17579472

10

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM. Griffiths GL, et al. J Nucl Med. 2003 Jan;44(1):77-84. J Nucl Med. 2003. PMID: 12515879 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

54 results

Results by year